Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobramycin Inhalation Powder Dosing in Cystic Fibrosis
NCT02015663Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jan 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tobramycin in Pseudomonas aeruginosa infection, sponsored by Novartis. Started Jan 2014; status: terminated.
02
Drugs
tobramycin
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02015663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015663.